accountDURECT Corporation announced Wednesday that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to evaluate ELADUR (TRANSDUR-...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Durect: King Pharmaceuticals Commences Phase IIb Eladur Clinical...
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account